Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 11/20 | 0.55 |
| ▸ | KLKB1 | P03952 | 5/20 | 0.51 |
| ▸ | GRN | P28799 | 1/20 | 0.48 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.48 |
| ▸ | KCNJ6 | P48051 | 1/20 | 0.42 |
| ▸ | KCNJ5 | P48544 | 1/20 | 0.42 |
| ▸ | KCNJ3 | P48549 | 1/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6761636 | 0.81 | F10 (0.56) | F10 | |
| SCHEMBL950904 | 0.80 | GRN (0.72) | KLKB1GRNSORT1KCNJ6KCNJ5 | |
| SCHEMBL950585 | 0.80 | KLKB1 (0.52) | KLKB1GRNSORT1PTGS1 | |
| SCHEMBL27520725 | 0.78 | KLKB1 (0.44) | F10KLKB1GRNSORT1 | |
| SCHEMBL28310655 | 0.77 | KLKB1 (0.46) | F10KLKB1GRNSORT1KCNJ6 | |
| SCHEMBL25428227 | 0.76 | KLKB1 (0.52) | F10KLKB1GRNSORT1KCNJ6 | |
| SCHEMBL29766798 | 0.76 | KLKB1 (0.52) | F10KLKB1GRNSORT1KCNJ6 | |
| SCHEMBL8406109 | 0.75 | F10 (0.76) | F10KLKB1 | |
| SCHEMBL4474291 | 0.74 | KLKB1 (0.47) | F10KLKB1GRNSORT1 | |
| SCHEMBL21462630 | 0.74 | KLKB1 (0.59) | KLKB1GRNSORT1PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-6632815-B2 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | disclosed |
| US-20020091116-A1 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | MILLENNIUM PHARMACEUTICALS, INC. | 2002-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091116-A1 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | SERPINC1, TFPI, F2 | F10 11/4885KLKB1 67/4885GRN 530/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.